Source:http://linkedlifedata.com/resource/pubmed/id/21474179
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
8
|
| pubmed:dateCreated |
2011-7-18
|
| pubmed:abstractText |
The histone deacetylase inhibitor (HDACi) valproic acid (VPA) has been shown to be active on acute myeloid leukemia (AML) and refractory anemia with excess of blasts (RAEB). Thirty-one elderly AML/RAEB patients (AML n=25; RAEB n=6) with a high rate of comorbidity were entered in a phase II study with low-dose cytarabine (Ara-C) and VPA. Fitness was evaluated by means of the Comprehensive Geriatric Assessment (CGA), including the Cumulative Illness Rating Scale (CIRS) score, the self-sufficiency scores of Activity of Daily Living (ADL) and Instrumental Activity of Daily Living (IADL). Eight patients obtained a lasting complete remission and 3 other patients obtained hematologic improvement for a total response rate of 35%. Five of 11 responding patients were relapsed or resistant after a previous treatment with Ara-C. Seven of 11 responding patients were assessed as frail at enrollment and/or had IADL impairment. Grades 3 and 4 toxicities were mainly hematological. Low-dose Ara-C and VPA is a relatively non-toxic combination with good therapeutic activity in elderly patients with AML/RAEB. This therapeutic approach represents an alternative treatment for patients who cannot undergo standard induction therapy.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
1873-5835
|
| pubmed:author |
pubmed-author:AlvaroM GMG,
pubmed-author:BaraldiAA,
pubmed-author:CiravegnaGG,
pubmed-author:CorsettiM TMT,
pubmed-author:De PaolaDD,
pubmed-author:GattaAA,
pubmed-author:LevinDD,
pubmed-author:PerticoneSS,
pubmed-author:PietrasantaDD,
pubmed-author:PiniMM,
pubmed-author:PrimonVV,
pubmed-author:SalviFF,
pubmed-author:TonsoAA,
pubmed-author:ZallioFF
|
| pubmed:copyrightInfo |
Copyright © 2011. Published by Elsevier Ltd.
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
35
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
991-7
|
| pubmed:meshHeading |
pubmed-meshheading:21474179-Aged,
pubmed-meshheading:21474179-Aged, 80 and over,
pubmed-meshheading:21474179-Anemia, Refractory, with Excess of Blasts,
pubmed-meshheading:21474179-Anticonvulsants,
pubmed-meshheading:21474179-Antimetabolites, Antineoplastic,
pubmed-meshheading:21474179-Cytarabine,
pubmed-meshheading:21474179-Drug Therapy, Combination,
pubmed-meshheading:21474179-Feasibility Studies,
pubmed-meshheading:21474179-Female,
pubmed-meshheading:21474179-Follow-Up Studies,
pubmed-meshheading:21474179-Humans,
pubmed-meshheading:21474179-In Situ Hybridization, Fluorescence,
pubmed-meshheading:21474179-Leukemia, Myeloid, Acute,
pubmed-meshheading:21474179-Male,
pubmed-meshheading:21474179-Middle Aged,
pubmed-meshheading:21474179-Neoplasm Recurrence, Local,
pubmed-meshheading:21474179-Remission Induction,
pubmed-meshheading:21474179-Survival Rate,
pubmed-meshheading:21474179-Treatment Outcome,
pubmed-meshheading:21474179-Valproic Acid
|
| pubmed:year |
2011
|
| pubmed:articleTitle |
Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C.
|
| pubmed:affiliation |
Division of Hematology, Azienda Ospedaliera SS Arrigo e Biagio e Cesare Arrigo, Alessandria, Italy. mcorsetti@ospedale.al.it
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|